The frequency and clinical impact of HER2 alterations in lung adenocarcinoma

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Kim, Eun Kyung ^a   Kim, Kyung A ^a   Lee, Chang Young ^a   Shim, Hyo Sup ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ALK GENE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; EGFR GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HER2 GENE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ROS1 GENE; SEQUENCE ANALYSIS; SURVIVAL RATE; ADENOCARCINOMA; AGED; CANCER STAGING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC VARIATION; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PATHOLOGY; PROGNOSIS; PROTO ONCOGENE; RISK FACTOR;

ADENOCARCINOMA; ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENES, ERBB-1; GENES, RAS; GENETIC VARIATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 85011579204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171280     Document Type: Article

References (32)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29. doi:10.3322/caac.21254 PMID: 25559415
2. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543-550. doi:10.1038/nature13385 PMID: 25079552
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137. doi:10.1038/35052073 PMID: 11252954
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. doi:10.1056/NEJM200103153441101 PMID: 11248153
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697. doi:10.1016/S0140-6736 (10) 61121-X PMID: 20728210
6. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002;86:1449-1456. doi:10.1038/sj.bjc.6600286 PMID: 11986780
7. Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F, et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res. 2003;9:3645-3652. PMID: 14506153
8. Heinmoller P, Gross C, Beyser K, Schmidtgen C, Maass G, Pedrocchi M, et al. HER2 status in nonsmall cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res. 2003;9:5238-5243. PMID: 14614004
9. Mar. N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer. 2015;87:220-225. doi:10.1016/j.lungcan. 2014.12.018 PMID: 25601485
10. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Uehara T, Fujimoto M, et al. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer. 2014;85:373-378. doi:10.1016/j.lungcan. 2014.06.007 PMID: 25047676
11. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer. 2005;103:1865-1873. doi:10.1002/cncr. 20957 PMID: 15770690
12. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31:1997-2003. doi:10.1200/JCO.2012.45.6095 PMID: 23610105
13. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910-4918. doi:10.1158/1078-0432. CCR-12-0912 PMID: 22761469
14. Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, et al. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol. 2016;11:414-419. doi:10.1016/j. jtho.2015.10.025 PMID: 26723242
15. Li C, Sun Y, Fang R, Han X, Luo X, Wang R, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012;7:85-89. doi:10.1097/JTO.0b013e318234f0a2 PMID: 22071781
16. Lara PN Jr., Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004;5:231-236. PMID: 14967075
17. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004;22:1180-1187. PMID: 14981103
18. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 2004;15:19-27. PMID: 14679114
19. Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005;103:1670-1675. doi:10.1002/cncr.20950 PMID: 15751020
20. De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76:123-127. doi:10.1016/j.lungcan. 2012.01.008 PMID: 22325357
21. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Part IV. Thorax. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010. pp. 251-270.
22. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Tumours of the lung. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer; 2015. pp. 9-151.
23. Hirsch FR, Varella-Garcia M, Bunn PA Jr., Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807. PMID: 12953099
24. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997-4013. doi:10.1200/JCO.2013.50.9984 PMID: 24101045
25. Suzuki M, Shiraishi K, Yoshida A, Shimada Y, Suzuki K, Asamura H, et al. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation. Lung Cancer. 2015;87:14-22. doi:10.1016/j.lungcan. 2014.10.014 PMID: 25468202
26. Kobyakov DS, Avdalyan AM, Bobrov IP, Bychkova EY, Lazarev AF, Lushnikova EL, et al. Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer. Bull Exp Biol Med. 2014;157:789-793. doi:10.1007/s10517-014-2668-9 PMID: 25348568
27. Al-Saad S, Al-Shibli K, Donnem T, Andersen S, Bremnes RM, Busund LT. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. J Thorac Oncol. 2010;5:1536-1543. doi:10.1097/JTO. 0b013e3181ea510a PMID: 20802349
28. Korrapati V, Gaffney M, Larsson LG, Di Nunno L, Riggs M, Beissner RS, et al. Effect of HER2/neu expression on survival in non-small-cell lung cancer. Clin Lung Cancer. 2001;2:216-219. PMID: 14700481
29. Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol. 2010;5:1922-1932. PMID: 21155183
30. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2:922-933. doi:10.1158/2159-8290. CD-12-0108 PMID: 22956644
31. Planchard D, Loriot Y, Andre F, Gobert A, Auger N, Lacroix L, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26:2073-2078. doi:10.1093/annonc/mdv319 PMID: 26269204
32. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431:525-526.